Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Concordance between physician response assessment and a novel method per Lugano criteria in patients with lymphoma using real-world data. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback